TECENED W. TED STATES PATENT AND TRADEMARK OFFIC In re Application of: Ulrich SPECK et al Serial No.: 09/446,328 Group Art Unit: 1619 Filed: 17 April 2000 Examiner: G. Hollinden For: USE OF INTRAVENOUS CONTRAST MEDIA FOR PROJECTION MAMMOGRAPH INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98 **Assistant Commissioner for Patents** Washington, D. C. 20231 I hereby certify that this correspondence is being deposited with the U.S. Postal Services as First Class Mail in an envelope addressed To: Commissioner of Patents and Trademarks. Washington, D.C. 20231 On: Name: **CITED MATERIALS** Signature: Date: . Applicant(s) hereby disclose the information listed in the attached form PTO-1449. Copies of materials listed but not attached were cited in parent application Serial No. ____; see 37 C.F.R. § 1.98(d). Copies of materials listed but not attached were cited in an International Search Report dated _____; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed ADDITIONAL INFORMATION [NONE?] **LANGUAGE** All listed materials are in the English language; see 37 C.F.R. § 1.98.

 \boxtimes Non-English language references:

> The reference(s): in the English-language is (are) indicated by commercial data bases to correspond to the reference(s): , respectively.

> (An) English-language translation(s) of the references: is (are) provided.

> A commercial English-language abstract of reference(s) is (are) provided.

> An English-language search report or an equivalent paper from a foreign patent office translated into English in pertinent part in connection with a counterpart foreign application, is provided indicating the relevance of the cited reference(s).

07/12/2002 GGEBREGI 00000045 09446328

Sir:

02 FC:126

FEES No fee is required for this Information Disclosure Statement because: This Information Disclosure Statement is being filed within three months of the filing date of a national application (other than a CPA) under § 1.53(d) or within 3 months of the date of entry of the national stage under § 1.491 in an international application; This Information Disclosure Statement is being filed before the mailing of a first action on the merits; This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that closes prosecution in the application, and is accompanied by a certification below. This Information Disclosure Statement is filed under 37 C.F.R. § 1.97(i). A fee is required for this Information Disclosure Statement: \boxtimes This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p). This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below. **CERTIFICATION** Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.

No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR §

1.56(c), more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$180.00. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,

Csaba Henter, Reg. No. 50,908 Attorney/Agent for Applicants 7

MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333

Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1653

Date: July 1, 2002

CH:jph

K:\Sch\1653\Information Disclosure Statement.doc